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catheterization procedure. Cardiac output was measured using the thermodilution technique 
with room temperature saline indicator injections made into the superior vena cava and 
blood temperature changes measured by a thermistor microprobe positioned in the aortic 
arch. The administration of CO (i.p.) in doses of 4-6 ml/kg caused a significant decrease in 
systemic arterial pressure (SAP) and systemic vascular resistance (SVR) but produced no 
significant changes in PA pressure. However, when pulmonary vascular resistance (PVR) 
was increased the i.p. administration of CO produced significant decreases in SVR and 
PVR. Ventilation with a 10% oxygen mixture produced a significant increase in PVR that 
was blocked by the prior administration of CO 8 ml/kg i.p. The heine oxygenase inhibitor 
chromium mesoporphyrin in the dose of 45 umol/kg Lp. caused a significant increase in 
SVR and a small decrease in PVR and similar changes were observed in animal pretreated 
with nitric oxide synthase inhibitor. These results suggest that CO has significant vasodilator 
activity in the systemic and pulmonary vascular beds and possesses the ability to modulate 
the pressor response toventilatory hypoxia. Moreover, these data suggest that endogenous 
CO production may play a role in the regulation of vasomotor tone in the rat. 
1082-73 CVT3146, a Novel A2A Receptor Agonist, Selectively 
Dilates the Coronary Circulation in Conscious Dogs 
Gona Zhao. Xiaobin Xu, Manuel Ochoa, Francis Belloni, Luiz Belardenilli, Thomas H. 
Hintze, CV Therapeutics, Palo Alto, California, New York Medical College, Valhalla, New 
York. 
Background: Adenosine (ADO) has been used as a coronary dilator for cardiac imaging. 
However, the ultra-short duration of the coronary vasodilation, and side effects by ADO 
make it a less ideal agent for the pharmacological test. CVT3146 is a novel, short-lasting 
A2A agonist. The study was to determine the effect of adenosine and CVT3146 on the 
coronary circulation and peripheral resistance in conscious dogs. 
Methods: Dogs were chronically instrumented for measurements of cardiac output (CO), 
coronary blood flow (CBF) and arterial blood pressure. Late diastolic coronary resistance 
(LDCR) and total peripheral resistance (TPR) were calculated. 
Results: Bolus injections of CVT3146 ranging from 0.t to 2.5 pg/kg caused dose-depen- 
dent increases in CBF (27±5.8 to 195±19% from 48±3 ml/min) and decreases in LDCR 
(22±3 to 73±2% from 1.97±0.2 mmHg/ml/min). Adenosine ranging from 10 to 250 Hg/kg 
caused similar increases in CBF (40±9 to 164±23%) and decreases in LDCR (29±3 to 
72±2%). Hence, CVT3146 is 10O-fold more potent coronary vasodilator than adenosine. 
Both CVT3146 and adenosine caused similar small increases in CO. However, CVT3146 
caused significantly smaller decreases in TPR compared with adenosine. For instance, 
CV'1"3146 (0.1 to 2.5 ±g/kg) only decreased TPR from 2.1±0.5 to 23±1.3%, whereas, 
adenosine (10 to 250 ~Jg/kg) reduced TPR from 15±3.3 to 42¢2.6% (all P<0.05, com- 
pared with CVT3146) despite causing similar coronary vasodilation. The ratio of the 
decreases in LDCR over the decreases in TPR for CVT3146 (1.0 ~g/kg) and adenosine 
(100 ~Jg/kg) were 6.1±1.8 and 2.2±0.2, respectively. 
Conclusion: These results indicate that CVT3146 is more potent coronary than peripheral 
vasodilator. This selective coronary vasodilation by CVT3146 makes it an ideal candidate 
for cardiac stress imaging. 
1082-74 AnUoxidant N-Acetylcysteine Inhibits Vasoective 
Agents Potentiated Mitogenic Effect of Mildly Oxidized 
Low-Density Lipoprotein on Vascular Smooth Muscle 
Cells 
Takuva Watanabe. Takashi Katagiri, Rajbabu Pakala, Claude R. Benedict, Third 
Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan, 
Division of Cardiology, University of Texas-Houston Health Science Center, Houston, 
Texas. 
Background: Mildly oxidized low-density lipoprotein (mox-LDL) has been shown to 
induce monocyte-endothelial interactions and vascular smooth muscle celt proliferation, 
key events in the formation of the atherosclerotic lesion. Growth factors and vasoactive 
peptides are also thought o play a major role in atherogenesis. We examined the inter- 
action between mox-LDL and well-known vasoactive agents such as serotonin (5-HT), 
angiotensin II (Ang-II), endothelin-1 lET-l), or urotensin II (U-II) in inducing DNA synthe- 
sis in vascular smooth muscle cells (VSMCs). 
Methods: Growth-arrested VSMCs were incubated with different concentrations of native 
LDL, highy oxidized LDL (ox-LDL), or mox-LDL with 5-HT, Ang-It, ET-1, or U-II in the 
absence or presence of N-acety~cysteine. DNA synthesis in VSMCs was examined by 
[3H]thymidine incorporation into cellular DNA. 
Results: Mox-LDL and ox-LDL stimulated DNA synthesis in a dose-dependent manner 
with a maximal effect at 5 mg/ml (211%, 154%), which are significantly greater than that 
of native LDL (128%). 5-HT, Ang-II, ET-1, or U-II also stimulated [3H]thymidine incorpora- 
tion in a dose-dependent manner. 5-HT had a maximal stimulatory effect at a concentra- 
tion of 60 microM (205%), Ang-tl at 1.75 microM (202%), ET-1 at 0.1 microM (205%), and 
U-li at 0.05 microM (161%). When added together, non-mitogenic concentration of mox- 
LDL (100 ng/ml)-induced [3H]thymidine incorporation was potentiated by low concentra- 
tions of 5-HT (1 microM), Ang-II (0.5 microM), ET-1 (1 nanoM), or U-II (10 nanoM) (114% 
to 330%, 325%, 338%, or 345%, respectively). Synergistic interactions of mox-LDL with 
5-HT, Ang-II, ET-1, or U-II were significantly inhibited by N-acatylcysteine (400 microM), 
an intracellular free radical scavenger. 
Conclusions: Our results suggest that mild oxidation of LDL may enhance its atherogenic 
potential and exert a synergistic interaction with vasoactive agents in inducing DNA syn- 
thesis via the generation of reactive oxygen species in VSMCs. 
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1082-75 Azimilide Inhibits Outward Potassium Currents in 
Human Atrial Myocytes 
Fuhua Chen, Fardard Esrnailian, Wei Sun, Glenn T. Wetzel, Jonnalagedda S. Sarrna, 
Bramah N. Siogh, Thomas S. Klitzner, UCLA School of Medicine, Los Angeles, 
Califomia. 
Background: Studies in animal cell preparations suggest that azimilide may produce a 
more desirable rate-dependent profile of Class III action as a result of its effects on both 
the slowly (IKs) and rapidly (IKr) activating components of IK. However, relatively little is 
known about the effects of azimilide on K+ currents in human atrial cells. The purpose of 
the present study is to study the effect of the novel antiarrhythmic agent, azimilide, on 
delayed rectifier potassium current (IK), the ultrarapid delayed rectifier current (IKur), and 
transient outward potassium current (IKto) in human atrial myocytes. 
Methods: The tight-seat, whole-cell voltage clamp technique was used to investigate the 
acute effects of azimilide on outward K+ currents in single human atrial myooytas. The 
cells were isolated enzymatically from atrial tissues, obtained from patients undergoing 
coronary bypass surgery, with institutional Review Board approval. 
Results: The average cell capacitance of the human atrial myocytes was 67:1:5.6 pF 
(Mean+SEM, n=11). Perfusion with 10 pM azimilide for 8 rain inhibited IK by 39% (from 
4.1_+0.8 to 2.8i-0.5 pA/pF, n=6, p<0.01) at the clamping membrane potential of +40 mV. 
Perfusion with the specific IKr blocker, E-4031 (10 p.M and 20 ~.M), did not significantly 
alter the current amplitude, suggesting that IKs is the dominant component of IK. Human 
atrial cell IKur was inhibited with azimilide (10 ~M) by 33% (from 3.6+0.5 to 2.4i,-0.3 pN 
pF, n=6, p<0.05). We also found that the average peak current amplitude of IKto in these 
cells was significantly inhibited with 10 ~M azimilide by 35% (from 7.6:L~0.9 to 4.9i-0.6 pN 
pF, n=6, p<0.01). 
Conclusion: The present study provides direct evidence that azimilide inhibits cellular 
membrane outward IKs, IKur and IKto in human atrial myooytes. Inhibition of these out- 
ward K+ currents by azimilide, especially of IKs and IKur, may have important clinical 
implications for its antiarrhythmic profile. 
1082-76 Divergent Effects of Short- and Long-Term Exposure to 
Aspirin on Basal and Beta-Adrenoceptor Stimulated 
Nitric Oxide Synthase Activity in Plateleta 
Peter D. O'Kane, Lindsey Queen, Graham Jackson, Albert Ferro, SL Thomas'Hospital, 
London, United Kingdom. 
Background: Important aspects of human platelet function depend on the activity of both 
nitric oxide synthase (NOS) and cyclooxygenase (COX). We examined the effects of 
acute and chronic aspirin exposure on basal and beta-2-edrenooeptor-mediated (B2-AR) 
ptatelst NOB activation and forearm blood flow responses. 
Methods and Results: Platetet NOS activity was measured from the conversion of L- 
[3H]arginine to L-[3H]citrulline, in platelets from healthy subjects before and after stimula- 
tion with B2-AR agonists. Ptatatet L-[3H]citrulline increased significantly above basal fol- 
lowing in vitro treatment with aspirin 0.4mmol/L or 4mmol/L (0.39 ¢ 0.10 to 0.61 ± 0.14 
and 0.32 ± 0.05 to 0.55 ± 0.08 pmol/10A8 platelets respectively, p<O.001 and n=14 for 
each), but not with indomethecin 0.1mmol/L (n=13). Albutarol also increased platslet 
NOS activity in the absence or presence of indomethacin or aspirin 0.4mmol/L, but not in 
the presence of aspirin 4mmol/L. Albutarol-induced vasodilation in the forearm, as mea- 
sured by venous occlusion plethysmography, was not affected by administration of 
800rag aspirin intravenously (n=6). By contrast, chronic low-dose aspirin therapy (75rag 
daily for 14 days, n=9) did not affect basal platelet NOS activity, but abolished B2-AR- 
mediated NOS activation: the increase in L-[3H]citrulline to isoproterenol lumol/L was 
44,0 ± 20.3% before and -12.7 ± 6.7% after aspirin, and that to albuterol lumol/L was 
48.1 ± 6.9% before and -3.9 ± 11.7% after aspirin (P<0.05 for each). 
Conclusions: Aspirin activates platelet NOS acutely in vitro through a mechanism proba- 
bly independent of COX inhibition. At high concentration, aspirin can also inhibit ptatelet 
B2-AR-mediated NOS activation. Following long-term low-dose aspirin, platelet basal 
NOS activity is unchanged but B2-AR-mediatad NOS activation is abolished. These find- 
ings suggest that aspirin has divergent effects on platelet NOS following short- and long- 
term exposure, and this may have important therapeutic implications, particularly in 
patients with established coronary artery disease, 
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1083-69 Variants of the Lipoprotein Lipase Gene Associate With 
Altered Lipid/Lipoprotein Profiles in the Caerphilly 
Heart Disease Study 
Rai K. Mattu, Edward W. Needham, Dimifri J. Richter, Manola Soccio, Jasper Trevelyan, 
Peter Elwood, John W. Yarnell, University Hospitals Coventry and Warwickshire &
University of Warwick, Coventry, United Kingdom, MRC Epidemiology Unit, Psnarth, 
United Kingdom. 
Background: Epidemiological studies demonstrate a strong link between dyslipidaemia 
and coronary heart disease (CHD). High-density lipoprotein cholesterol (HDL-C) levels 
have a potent inverse relationship with CHD and elevations of triglycerides and total cho- 
lesterol (TC) confer direct risk. Lipoprotein lipase (LPL) is a rata-limiting enzyme in the 
clearance of triglyceride rich lipoproteins and is important in the activation of HDL parti- 
cles for reverse cholesterol transport. Recent data implicated two LPL gene mutations, 
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Asp9-Asn (exon 2) and Asn291-Ser (exon 6), in decreased LPL activity and reduced 
HDL-C levels amongst patients with familial combined hyperlipidaemia. We investigated 
the potential influence of these mutations upon serum lipids/lipoproteins amongst the 
representative, homogeneous, adult male population of Caerphilly. 
Methods: 2,316 men were purposely recruited into the Caerphilly Prospective Heart Dis- 
ease Study, when they were aged between 45-59 years, to prospectively screen and 
monitor them for CHD and its risk factors. DNA was available for genotyping on 1,958 
men from the phase 2 collection. We genotype d them for these mutations and the data 
was assessed using non-parametric statistical analyses. 
Results: The T2 (Asp9-Asn) and R2 (Asn291-Ser) alleles denote restriction sites for the 
Taql and Rsal enzymes, respectively. Men possessing the T1 allele had significantly 
raised levels of apo-A1 (131.3 mg/dl vs 124.9 mg/dl, p=0.009), the major surface protein 
activating HDL. Whilst individuals possessing the R2 allele had significantly reduced 
HDL-C levels (0.90 mmol/I vs 1.02 mmol/1, p--O.006) and increased TC/HDL-C ratios 
(6.73 vs 5.84, p=0.043). Interestingly, our cohort did not have any R2R2 homozygotes. 
Conclusions: Our data suggests that the LPL gene influences lipids/ lipoproteins and 
dyslipideemia mongst he UK adult, male population. 
1083-70 Modulation by TGF-Betel  of  Oxldlzed-LDL-Induced 
Upregulat lon of P-Selectln and IGAM-1 and Monocyte 
Adhesion in Human Coronary Endothelial Cells 
Jawahar L. Mehta, Honoiiano Chen, Dayuan Li, University of Arkansas for Medical 
Sciences, Little Rock, Arkansas, Central Arkansas Veterans Healthcare System, Little 
Rock, Arkansas. 
Background: Oxidized-LDL (ox-LDL) upregulates expression of LOX-1, a specialized lec- 
tin-like receptor, on endothelial cells. Uprsgulation of LOX-1 is associated with expression 
of adhesion molecules and monocyte adhesion to endothelial cells. This mechanism may 
relate to the pathogenicity of ox-LDL in atherogenesis. Further, TGF-betal has been postu- 
lated to exert tissue protective and anti-atherogenic effect. We designed this study to inves- 
tigate the role of TGF-betal in ox-LDL-induced expression of adhesion molecules and 
monocyte adhesion to human coronary artery endothelial cells (HCAECs). 
Methods and results: Fifth generation cultured HCAECs were incubated with native-LDL or 
ox-LDL (10-40 mg/ml) for 1-24 hrs. Parallel sets of HCAECs were treated with a specific 
antibody to LOX-1 (10 mg/ml) or to recombinant TGF-betal (2 ng/ml) before incubation 
with ox-LDL (40 mg/ml). Incubation of HCAECs with ox-LDL, but not native-LDL, signifi- 
cantly increased expression P-selectin and ICAM-1 (Western analysis) and monocyte 
adhesion to HCAECs (all P<0.01 vs. n-LDL, n=5). Ox-LDL also decreased active TGF- 
bets1 levels (measured by ELISA) in a time- and concentration-dependent manner 
(P<0.05 vs. control). Antibody to LOX-1 attenuated the reduction in TGF-betal levels 
(P<0.05 vs. ox-LDL alone). Simultaneously, recombinant TGF-betal reduced the expres- 
sion of P-selectin and ICAM-1, as well as monocyte adhesion to HCAECs induced by ox- 
LDL (all P<0.02, n=5). 
Conclusion: This study shows that 1) ox-LDL decreases active TGF-betal levels by activa- 
tion of LOX-1; 2) the reduction in active TGF-betal may be the basis of ox-LDL-mediated 
upregulation of P-selsctin and ICAM-1 expression and monocyte adhesion to HCAECs. 
1083-71 A Cholesteryl Ester Transfer Protein Inhibitor Increased 
In Vlvo Synthatlc Rates and Liver mRNA Levels of 
Apol lpoprofein A-I 
Eiso Shimoji, Bo Zhano, Ping Fan, Keijiro Saku, Fukuoka Universi~ Fukuoka, Japan. 
Background: Patients with cholesteryl ester transfer protein (CETP) deficiency have 
increased HDL-C levels, and the inhibition of CETP activity has been shown to increase 
apolipoprotein (ape) A-I levels and suppress the progression of atheroosclerosis n choles- 
terol-fed rabbits. To clarify the mechanism by which CETP inhibition increases serum apo 
A-I levels, the effects of a CETP inhibitor, JTT-705, on in vivo apo A°I kinetics and tissue 
apo A-I gene expression were investigated. 
Methods: Japanese White rabbits were randomly fed a diet with (n=8, treated) or without 
(n=10, controls) 0.75% J'l-r-705 (Japan Tabasco Inc.) for 7 mo. CETP activities and 
serum levels of apo A-I and HDL-C levels were measured. Apo A-I kinetics were per- 
formed by injecting radioiodinated apo A-I, which was freshly prepared by the guanidine 
HCI method. Apo A-I mRNA levels in the liver and intestine were quantified by SYBR 
real-time RT-PCR. 
Results: JTT-705 inhibited 32.0% of the CETP activity and increased (p<0.05) the serum 
levels of HDL-C and apo A-I (66.5 ± 13.7 vs. 42.9 ± 6.2 mg/dL). Treated rabbits had a 
greater (p<O.05) synthetic rate (SR) of HDL-apo A-I than control rabbits (13.1 ± 2.6 vs. 
10.0 ± 1.9 mg/Kg/day), while the fractional catabolic rates in the two groups were similar 
(0.47 ± 0.10/day and 0.52 ± 0.09/day). JTT-705 increased apo A-I mRNA levels In the 
liver but not In Inteetlne (Figure). 
Conclusion: Increased SR and liver gene expression of apo A-I contribute to the 
increased serum apo A-I levels induced by CETP inhibition. 
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1083-95 Mutation In the Promoter Region of the Hepatic Lipase 
Gene Correlates With Dysl ipidemia In Type 2 Diabetes 
RaJ K. Mattu. Edward W. Needham, Jasper Trevelyan, Dimitri J. Richter, Maria A. 
Adiseshiah, Mauro Lencioni, Shane Gieewarsingh, D. John Befferidge, University 
Hospitals Coventry & Warwickshire &University of Warwick, Coventry, United Kingdom, 
University College London Medical School, London, United Kingdom. 
Background: Cardiovascular disease remains the major cause of morbidity and mortality 
amongst ype II diabetics. The total coronary heart disease risk of these patients is much 
higher than for non-diabetics at every level of given risk factor, such as dyslipidaemia. 
About 40% of diabetics have hypertriglyceridaemia (HTG) and reduced high-density Iipo- 
protein cholesterol (HDL-C). Hepatic lipase (HL) is a key enzyme in the hydrolysis of trig- 
lycerides in the core of remnant lipoprotein particles and facilitates activation of HDL 
particles. It therefore influences serum triglycedde and HDL-C levels and may be an 
important determinant of the dyslipidaemia observed amongst diabetics. A C-514-T 
mutation involving the promoter egion of the HL gene associates with reduced HL activ- 
ity and increased HDL2 levels, hence we examined whether this mutation related 10 
serum lipids amongst ype II diabetics. 
Methods: We recruited 386 consecutive patients attending the diabetes clinic. All cardio- 
vascular risk factors were characterised and studied once the patient's diabetic control 
had become satisfactory. Patient lipids were analysed without lipid modifying drugs. 
Patients were genotyped using the polymerase chain reaction. 
Results: Triglyceride levels were significantly higher (3.25 vs 2.53 retool/I, p=0.03) 
amongst diabetics possessing the TT genofype. Furthermore, subjects possessing the 
C-514-T promoter mutation had a 78% increased risk of being in the highest tertile of the 
total cholesterol/HDL-C ratio distribution, O.R. 1.78 (1.00-3.17, p=0.048). 
Conclusions: Mutation of the promoter egion of the hepatic lipase gene may predispose 
type II diabetic patients to a deleterious lipid profile and possibly influence their coronary 
heart disease risk. 
1083-96 Increasing Testosterone Lowers High Density 
Lipoproteln Cholesterol by Decreasing Apol lpoproteins 
AI and All 
John A. Morrison, Dennis L. Sprscher, Bruce A. Barton, Children's Hospital Medical 
Center, Cincinnati, Ohio, Maryland Research Institute, Baltimore, Maryland. 
Background: During puberty, high density lipoprotein cholesterol (HDL-C) and its major 
associated apolipoproteins (apo), AI and All, decrease markedly in males, but not in 
females, resulting in the recognized sex differences in lipid profiles and attendant risk to 
coronary heart disease. The timing of the changes has implicated sex steroid hormones, 
especially free testosterone (T) in the changes. Previous studies of pubertal males have 
been limited by small samples, cross sectional designs, or longitudinal designs using 
only two points in time, design elements that restrict he power of the studies. 
Methods: To explicate the role of free T in the pubertal changes in adolescent male lipids 
we followed 251 black and 283 white males, ages 10-15 yrs at enrollment, for three 
years. We measured lipid profiles, free testosterone (T), estradiol, and body mass index 
(BMI = kg/m2) every 6 months and apo AI and All annually. 
Results: Controlling for pubertal stage, black males had higher HDL-C, apoAI, (all 
p<.001), and apoAII (p=.06) than white males. With advancing pubertal stage, HDL-C, 
apoAI and All decreased in both black and white boys. Longitudinal, multivariate analy- 
ses (General Estimating Equations) showed that increasing free T associated with 
decreasing HDL-C, apo AI and All (all p<.01), but did not affect the ratio of HDL-C to 
apoAI and All. When apoAI and All were entered into the model for changes in HDL-C as 
predictors, they contnbuted significantly to decreases in HDL-C. At this point, however, 
free T dropped out of the model, suggesting that the effects of free T on HDL-C are medi- 
ated through apoAI and All concentrations. Increasing BMI associated with lower HDL-C 
and HDL-C/(apoAI and All) ratios but did not associate with changes in apoAI. Estrediol 
was not associated with changes in HDL-C, apo AI or All. 
Conclusions: During puberty, increasing T appears to contribute to lower HDL-C by low- 
ering the apolipoproteins (apoAI and All) available to these particles, not by altering the 
amount of lipid associated with these protein moieties. 
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1084-90 Ezatimlbe Co-Administered With Slmvastatin in 668 
Patients With Primary Hyperch01esterolemia 
Michael Davidson, Thomas McGarry, Robed Battis, Lorenzo Melani, Leslie Lipka, 
Alexandre LeBeaut, Ramachandrsn Suresh, Steven Sun, Enrico Veltri, for the Ezetimibe 
Study Group, Chicago Center for Cardiovascular Research, Chicago, Illinois, Oklahoma 
Foundation for Clinical Research, Oklahoma Ci~ Oklahoma. 
Background: This Phase III, randomized, double-blind, placebo-controlled study evalu- 
ated the efficacy and safety of ezetimibe (EZE) administered with simvastatin (SIM) in pts 
with primary hyparcholesterolemia. 
Methods: After dietary stabilization (NCEP Step 1 or stricter diet), a 2-12 wk screening/ 
washout period and a 4-wk, single-blind, PBO lead-in period, 668 pts with baseline LDL- 
C _>145 mg/dl to -<250 rag/all and TG -<350 rag/all were randomized to 1 of the following 
administered aily for 12 consecutive wks: EZE 10 rag; SIM 10, 20, 40 or 80 rag; EZE mg 
